Express News | Alkermes Expects To Initiate Vibrance-2 Phase 2 Study In Narcolepsy Type 2 In 2H 2024
Moomoo 24/7Apr 24 07:05 ET
Express News | Alkermes Initiates Vibrance-1 Phase 2 Study Of ALKS 2680 For Narcolepsy Type 1
Moomoo 24/7Apr 24 07:04 ET
Express News | Alkermes PLC: Expects to Initiate Vibrance-2, a Planned Phase 2 Study in Patients With Narcolepsy Type 2, in Second Half of 2024
Moomoo 24/7Apr 24 07:00 ET
Express News | Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating Alks 2680 for the Treatment of Narcolepsy Type 1
Moomoo 24/7Apr 24 07:00 ET
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
DUBLIN, April 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared
AlkermesApr 24 00:00 ET
Alkermes (NASDAQ:ALKS) Shareholders Have Endured a 20% Loss From Investing in the Stock a Year Ago
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. That
Simply Wall StApr 23 13:50 ET
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanksApr 19 06:30 ET
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Alkermes Price Target Maintained With a $35.00/Share by HC Wainwright & Co.
Dow JonesApr 19 06:27 ET
Express News | HC Wainwright & Co. Reiterates Neutral on Alkermes, Maintains $35 Price Target
Moomoo 24/7Apr 19 06:17 ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanksApr 18 01:10 ET
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Yahoo FinanceApr 17 10:01 ET
Alkermes to Report First Quarter Financial Results on May 1, 2024
DUBLIN, April 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company
AlkermesApr 17 00:00 ET
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
TipRanksApr 12 01:41 ET
Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges
TipRanksApr 12 01:38 ET
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Yahoo FinanceApr 11 10:15 ET
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), DocGo (DCGO) and Alkermes (ALKS)
TipRanksApr 10 07:20 ET
Balanced Hold Rating for Alkermes Amidst Promising Data and Development Risks
TipRanksApr 10 06:26 ET
Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential
TipRanksApr 9 20:55 ET
Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says
On Tuesday, Alkermes plc (NASDAQ:ALKS) revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680 for
BenzingaApr 9 14:23 ET
Alkermes on the Rise: A Promising Outlook for Narcolepsy Treatment With ALKS 2680
TipRanksApr 9 13:05 ET
No Data
No Data